Want to see IN:KREBSBIO full AI Analyst Report?

Krebs Biochemicals & Industries Ltd. (KREBSBIO) Price & Analysis

0 Followers

KREBSBIO Stock Chart & Stats

₹71.00

-₹2.80(-2.89%)

At close: Jan 08 4:00 PM EST

₹71.00

-₹2.80(-2.89%)

Day’s Range― - ―

52-Week Range₹38.52 - ₹81.80

Previous CloseN/A

Volume3.29K

Average Volume (3M)726.00

Market Cap

₹1.16B

Enterprise Value₹3.71K

Total Cash (Recent Filing)₹1.29M

Total Debt (Recent Filing)₹2.25B

Price to Earnings (P/E)―

Beta1.44

Next Earnings

Nov 10, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-7.86

Shares Outstanding21,560,587

10 Day Avg. Volume346

30 Day Avg. Volume726

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)-0.53

Price to Sales (P/S)3.61

P/FCF Ratio-7.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Product Mix: APIs And Specialty ChemicalsSelling active pharmaceutical ingredients and specialty/industrial chemicals provides durable B2B demand from pharma and industrial customers. This product mix supports repeat contractual supply relationships and less price sensitivity than commodity chemicals, aiding stable revenue potential over months.

Technical Manufacturing CapabilityExperience in fermentation- and synthesis-based processes reflects specialized technical know-how and regulatory familiarity. These capabilities create higher barriers to entry and support qualification requirements for pharma customers, helping preserve customer relationships and margins over the medium term.

Gross Margin RecoveryReverting to positive gross margins suggests improved unit economics via pricing, cost control, or mix shift. Sustained positive gross margin is a prerequisite for durable operating leverage and meaningful profit recovery, reducing ongoing cash burn risk if the trend persists.

Bears Say

Persistent Net LossesLarge, recurring net losses materially erode capital and limit internal reinvestment. Over a multi-month horizon, sustained losses increase dependency on external financing, constrain strategic choices, and raise the chance that operational fixes will be insufficient without capital or structural change.

Negative Shareholders' Equity And Heavy LeverageNegative equity combined with heavy debt elevates refinancing and solvency risk. This structural balance-sheet weakness limits access to credit, can trigger covenant pressure, and reduces flexibility for capex or working-capital needs, making the business vulnerable over the coming months.

Weak And Inconsistent Cash GenerationPersistent negative operating and free cash flow indicate ongoing cash burn and reliance on outside funding. Even with some improvement, sustained negative cash generation constrains the company's ability to service debt, invest in operations, or withstand industry shocks in the medium term.

Krebs Biochemicals & Industries Ltd. News

Krebs Biochemicals Board Clears Q3 FY2025 Unaudited Results After Clean Review

Krebs Biochemicals & Industries Ltd. ( ($IN:KREBSBIO) ) has shared an update. Krebs Biochemicals & Industries Ltd. announced...

6M ago

Krebs Biochemicals to Shut Trading Window Ahead of Q3 Results

Krebs Biochemicals & Industries Ltd. ( ($IN:KREBSBIO) ) just unveiled an update. Krebs Biochemicals & Industries Ltd. has...

8M ago

KREBSBIO FAQ

What was Krebs Biochemicals & Industries Ltd.’s price range in the past 12 months?

Krebs Biochemicals & Industries Ltd. lowest stock price was ₹38.52 and its highest was ₹81.80 in the past 12 months.

What is Krebs Biochemicals & Industries Ltd.’s market cap?

Krebs Biochemicals & Industries Ltd.’s market cap is ₹1.16B.

When is Krebs Biochemicals & Industries Ltd.’s upcoming earnings report date?

Krebs Biochemicals & Industries Ltd.’s upcoming earnings report date is Nov 10, 2026 which is in 95 days.

How were Krebs Biochemicals & Industries Ltd.’s earnings last quarter?

Krebs Biochemicals & Industries Ltd. released its earnings results on Aug 07, 2026. The company reported -₹1.152 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Krebs Biochemicals & Industries Ltd. overvalued?

According to Wall Street analysts Krebs Biochemicals & Industries Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Krebs Biochemicals & Industries Ltd. pay dividends?

Krebs Biochemicals & Industries Ltd. does not currently pay dividends.

What is Krebs Biochemicals & Industries Ltd.’s EPS estimate?

Krebs Biochemicals & Industries Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Krebs Biochemicals & Industries Ltd. have?

Krebs Biochemicals & Industries Ltd. has 21,560,587 shares outstanding.

What happened to Krebs Biochemicals & Industries Ltd.’s price movement after its last earnings report?

Krebs Biochemicals & Industries Ltd. reported an EPS of -₹1.152 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.146%.

Which hedge fund is a major shareholder of Krebs Biochemicals & Industries Ltd.?

Currently, no hedge funds are holding shares in IN:KREBSBIO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Krebs Biochemicals & Industries Ltd.

Established in 1991 and headquartered in Hyderabad, India, Krebs Biochemicals & Industries Limited primarily focuses on the production and distribution of active pharmaceutical ingredients (APIs) across India. The company also innovates by developing biotechnological processes applicable to the medical, agricultural, and industrial sectors. Its current portfolio includes compounds like androstenedione, lovastatin, and simvastatin, which serve as steroid intermediates and anti-cholesterol agents. Furthermore, Krebs Biochemicals is actively developing new products such as amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine, targeting diverse therapeutic applications including anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough relief. The firm also extends its expertise by offering contract manufacturing services to large pharmaceutical and multinational corporations.